Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial.

Key Takeaways for GI Nurses

• The SCREESCO trial provides high-quality evidence comparing colonoscopy screening directly against fecal immunochemical testing (FIT) and usual care, offering valuable data to support patient education discussions about screening modalities
• Understanding comparative effectiveness between screening methods helps nurses provide more informed counseling to patients weighing the benefits and logistics of different colorectal cancer screening approaches
• This randomized controlled trial design strengthens the evidence base that nurses can reference when discussing screening compliance and effectiveness with hesitant patients or those choosing between screening options
• Results from this study may influence future screening protocols and patient flow patterns in endoscopy units as healthcare systems optimize their colorectal cancer prevention strategies

Clinical Relevance

For endoscopy nurses, this research directly impacts daily practice through enhanced patient education capabilities and screening program support. When patients present with questions about whether to pursue colonoscopy versus FIT testing, nurses can reference evidence-based comparative data to help patients make informed decisions. This is particularly valuable during pre-procedure consultations and screening program outreach, where nurses often serve as primary educators helping patients understand their options and overcome barriers to screening participation.

The study's findings will likely influence unit operations and workflow planning as healthcare systems refine their colorectal cancer screening strategies. Endoscopy units may need to adjust capacity planning, patient scheduling patterns, and resource allocation based on how this evidence shapes institutional screening recommendations. Additionally, nurses involved in population health initiatives and screening coordination can use these results to advocate for evidence-based program design and to educate referring providers about optimal screening approaches for different patient populations.

From a professional development perspective, this research reinforces the importance of staying current with comparative effectiveness research in colorectal cancer screening. As the evidence base evolves, GI nurses must maintain competency in discussing the relative merits of different screening modalities, understanding patient factors that might favor one approach over another, and supporting shared decision-making conversations that align with current best practices and patient preferences.

Bottom Line

The SCREESCO randomized controlled trial provides GI nurses with robust comparative evidence between colonoscopy, FIT testing, and usual care approaches to colorectal cancer screening, strengthening our ability to provide evidence-based patient education and support informed screening decisions while potentially influencing future unit operations as healthcare systems optimize their screening programs based on this head-to-head effectiveness data.